Abstract

Messenger RNA (mRNA) introduction is a promising approach to produce therapeutic proteins and peptides without any risk of insertion mutagenesis into the host genome. However, it is difficult to introduce mRNA in vivo mainly because of the instability of mRNA under physiological conditions and its strong immunogenicity through the recognition by Toll-like receptors (TLRs). We used a novel carrier based on self-assembly of a polyethylene glycol (PEG)-polyamino acid block copolymer, polyplex nanomicelle, to administer mRNA into the central nervous system (CNS). The nanomicelle with 50 nm in diameter has a core-shell structure with mRNA-containing inner core surrounded by PEG layer, providing the high stability and stealth property to the nanomicelle. The functional polyamino acids possessing the capacity of pH-responsive membrane destabilization allows smooth endosomal escape of the nanomicelle into the cytoplasm. After introduction into CNS, the nanomicelle successfully provided the sustained protein expression in the cerebrospinal fluid for almost a week. Immune responses after mRNA administration into CNS were effectively suppressed by the use of the nanomicelle compared with naked mRNA introduction. In vitro analyses using specific TLR-expressing HEK293 cells confirmed that the nanomicelle inclusion prevented mRNA from the recognition by TLRs. Thus, the polyplex nanomicelle is a promising system that simultaneously resolved the two major problems of in vivo mRNA introduction, the instability and immunogenicity, opening the door to various new therapeutic strategies using mRNA.

Highlights

  • Messenger RNA has a high potential to produce proteins or peptides for therapeutic purposes in a safe manner without any risk of random integration into the genome

  • Polyplex nanomicelle allowed in vivo Messenger RNA (mRNA) introduction into central nervous system (CNS)

  • This study represents the advantages of the polyplex nanomicelle containing mRNA for providing therapeutic proteins and peptides to CNS by intrathecal injection

Read more

Summary

Introduction

Messenger RNA (mRNA) has a high potential to produce proteins or peptides for therapeutic purposes in a safe manner without any risk of random integration into the genome. Pioneering studies to transfect mRNA into cells using a nonviral method were reported in the 1980s [1,2], the interest in the clinical use of mRNA has been limited for a long time. Several groups recently induced pluripotent stem cells (iPSCs) by transfection of mRNA encoding Yamanaka factors [14,15,16]. Their success strongly suggests the feasibility of using mRNA for therapeutic purposes in the future; they generally performed repeat transfections with intervals of a few days, suggesting that the instability of mRNA hampered the durable protein expression after mRNA transfection

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call